[ad_1]
TAIZHOU, China, June 27, 2022 /PRNewswire/ — Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval (the “Clinical Trial Approval”) for its R520A, a mRNA COVID-19 vaccine (“R520A”), from the Food and Drug Administration of the Philippines.
R520A is an mRNA COVID-19 vaccine specifically targeting the Omicron variant developed by Wuhan Recogen Biotechnology Co., Ltd., a subsidiary of the Company. R520A adopts a self-developed lyophilization technology that can effectively sustain the physiochemical properties and bioactivity of mRNA- LNP and achieve long-term storage at 2℃–8℃. In the pre-clinical studies, the level of neutralizing antibody titers against Omicron variant increased to a high level of 4,758 and it can also induce neutralization response against Delta variant, indicating its promising immunogenicity profile. The relevant research results have been posted on the preprint server, bioRxiv.
About Recbio
Founded in 2012, Recbio is an innovative vaccine company. With the vision of “Become the Leader of Innovative Vaccine in the Future,” Recbio takes “Protect Human Health with Best-in-Class Vaccines” as…
Full story available on Benzinga.com
[ad_2]
Source link
